Page 1

● ● Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021 ● PRESS RELEASE cellectis Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or refractory multiple myeloma patients . EDITING LIFE Preclinical pipeline disclosed at Innovation Days : UCART20x22 for B - cell malignancies , UCARTMESO ( targeting mesothelin ) , and TALGlobin01 ( Sickle Cell Disease ) First mRNA batches and UCART training runs successfully completed in our proprietary GMP facilities Cash position¹ of $ 257 million as of June 30 , 2021. Cash runway into 2023 US & Canada only : +1 877-407-3104 August 5 , 2021 New York - Cellectis S.A. ( NASDAQ : CLLS - EURONEXT GROWTH : ALCLS ) ( the " Company " ) , a gene - editing platform company with clinical - stage immuno - oncology programs using allogeneic chimeric antigen receptor ( CAR ) T - cells and gene therapy programs for genetic diseases , today announced results for the three - month and first six - month periods ending June 30 , 2021 . International : +1 201-493-6792 Cellectis will hold a conference call for investors on Friday , August 6 , 2021 , at 8:00 AM ET / 2:00 PM CET . The call will include the Company's second quarter results , and an update on business activities . The live dial - in information for the conference call is : In addition , a replay of the call will be available until August 20th , by calling +1 877-660-6853 ( Toll Free US & Canada ) ; +1 201-612-7415 ( Toll Free International ) . Conference ID : 13721394 " To date , more than 120 patients have been treated with allogeneic CAR - T cells utilizing technology developed by Cellectis , both in Cellectis - sponsored clinical studies and those of our license partners Allogene and Servier . 1 1 Cash position includes cash , cash equivalent , current financial assets and restricted cash